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For the majority of families affected by one of the neuronal ceroid lipofuscinoses (NCLs), a biochemical and/or genetic diagnosis can be
achieved. In an individual case this information not only increases understanding of the condition but also may influence treatment choices and
options. The presenting clinical features prompt initial investigation and also guide clinical care. The clinical labels “infantile NCL”, “late infantile
NCL” and “juvenile NCL”, therefore remain useful in practice. In unusual or atypical cases ultra-structural analysis of white blood cells or other
tissue samples enables planning and prioritisation of biochemical and genetic tests.This review describes current methods available to achieve
clinical, pathological, biochemical and genetic diagnosis in children presenting with symptoms suggestive of one of the NCLs.
© 2006 Elsevier B.V. All rights reserved.Keywords: NCL; Diagnosis; Phenotype1. Introduction
Advances in our understanding of the underlying genetic and
biochemical pathogenesis of the neuronal ceroid lipofuscinoses
(NCLs) have translated into changes in the way this group of
disorders are now diagnosed. Before disease causing genes
were identified, diagnosis was largely based on histopatholo-
gical techniques. All the NCLs are characterised by the
intracellular accumulation of autofluorescent pigments (Fig.
2). Electron microscopic evaluation of the morphology of the
storage material, along with the age of onset and pattern of
symptoms enabled classification into one of the three main
childhood NCL types: infantile, late infantile and juvenile.
Over the last decade six NCL genes have been identified and
characterised. Undoubtedly more NCL genes exist [1]. It has
become increasingly clear that not only can mutations in a
number of genes result in similar clinical and histopathological
phenotypes (genetic heterogeneity) but that different mutations⁎ Corresponding author. Tel.: +44 207 188 4004; fax: +44 207 188 0851.
E-mail address: ruth.williams@gstt.nhs.uk (R.E. Williams).
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doi:10.1016/j.bbadis.2006.07.001in the same gene may result in markedly different clinical
phenotypes (allelic heterogeneity), and that the same genetic
mutation present within the same family can result in marked
clinical phenotypic variability. Thus the emerging story of the
NCLs and their classification has in fact become more complex
and confusing.
In this paper we shall attempt to describe current methods of
diagnosis and classification of the NCLs. For the practising
physician and child's family, a clinical diagnosis which implies
the age of onset and syndrome complex is still essential. An
understanding of the individual disease should be augmented
with a biochemical and genetic diagnosis wherever possible.
2. Diagnostic clinical features of the major childhood NCLs
2.1. Congenital NCL
10 cases of congenital NCL have now been described.
Affected infants present with congenital microcephaly, respira-
tory distress and status epilepticus. Death occurs within the first
few weeks of life. Neuropathological studies post mortem have
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osmiophilic deposits. Following the finding of mutations in the
Cathepsin D gene (CTSD) in similarly affected lambs,
abnormalities in human CTSD have recently been shown to
be the cause of human congenital NCL [2].
2.2. Infantile NCL
Infantile neuronal ceroid lipofuscinosis is caused by
mutations in CLN1, the gene encoding the enzyme palmitoyl
protein thioesterase 1 (PPT1). The clinical course and age of
onset of the disease vary much due to the different mutations
in CLN1 ranging from infantile-onset devastating disease to an
adult-onset form with symptoms presenting in the fourth
decade [3]. NCL caused by mutations in CLN1 with onset in
infancy, the classic INCL was first described in the 1970s in
Finland [4].
Children reach normal motor milestones during the first
year, but deceleration of head growth and muscular hypotonia
are detectable after the age of 6 months. Ataxia and motor
clumsiness develop together with irritability, sleep disturbance,
and visual failure leading to a rapid developmental deteriora-
tion during the second year of life. The fine motor skills are
affected with purposeless, characteristic hand movements
(hyperkinesias) like those seen in Rett syndrome. By the age
of 2–3 years the patients have lost all their motor abilities and
social interest, they are blind with increasing spasticity,
seizures and myoclonias. Death usually occurs between 8
and 13 years.
Neurophysiologic findings in infantile onset NCL caused
by mutations in CLN1 are non-specific following the rapid
neuronal degeneration and progression of the disease. The
first finding is decreased reactivity in EEG to passive eye
opening and closing around the age of 1 year, sleep spindles
are lost by the age of 2 years. By the age of 3 years EEG
becomes isoelectric together with extinction of first somato-
sensensory evoked potentials (∼2.5 years), then electroreti-
nogram (∼3 years), and last visual evoked potentials
(∼4 years).
2.3. Late infantile NCL and variants
2.3.1. Classical late infantile NCL
Classical late infantile NCL is caused by mutations in the
CLN2 gene leading to tripeptidyl-peptidase 1 deficiency
(TPP1). The disease manifests in a previously healthy child
around the third year of life. First symptoms are an unexpected
delay of psychomotor development or an epilepsy of sudden
onset. Seizures are generalized tonic–clonic or partial, fre-
quently of a severe myoclonic type. They may soon become
resistant to drug treatment.
Blindness eventually develops due to retinal atrophy. The
visual loss, however, is frequently incomplete during the early
course so that it may go unnoticed and prevent early suspicion
of a brain disease associated with retinal degeneration. The EEG
can give diagnostic hints by showing posterior spikes on slow
photic stimulation. In addition, electrophysiological studiesmay show increased evoked potentials. The electroretinogram is
reduced or absent early in the disease. Therapy is only
supportive. Valproate is often the preferred anticonvulsant.
Worsening of seizures treated with carbamazepine and some-
times with lamotrigine may be a useful diagnostic marker of a
progressive myoclonic epilepsy syndrome and alert the clinician
to the need for further investigation.
The children gradually lose all psychomotor abilities.
Swallowing becomes difficult. With artificial feeding and
good general care the patients may survive to the age of 10 to
15 years. A quantitative description of the clinical course in
patients with the most frequently encountered severe mutations
is given by Steinfeld et al. [5].
There are several clinical variants of late infantile NCL. In
these, the symptoms are similar to those of the classical type but
tend to occur somewhat later. Their overall course may be more
protracted.
2.3.2. Finnish variant late infantile NCL
This variant occurs almost exclusively in Finland. It is caused
by mutations in the CLN5 gene [6]. The first manifestations of
this variant (CLN5, vLINCLFinn) occur between the ages of 2
and 6 years [7]. These manifestations include attention deficit
and motor clumsiness. Thereafter, mental decline and visual
failure are noticed. In addition, epilepsy, ataxia, and myoclonic
jerks are important features of the disease. Specific EEG features
include posterior spikes to low-frequency photic stimulation,
ceasing after the age of 10 years [8,9]. Furthermore, giant
somatosensory evoked potentials (SEPs) are found. Age of the
death of the patients included in the previous reports varied
between 13 and 21 years [7,8].
2.3.3. Variant late infantile NCL
This variant was also referred to as “early juvenile NCL” and
may be caused by mutations in the CLN6 gene. It is mainly
found in the Czech Republic, Croatia, Portugal, Central and
South America, and, more rarely, in Central and Northern
Europe [10,11].
2.3.4. Turkish variants of late infantile NCL
A variant occurring in Turkish patients has been given the
genetic assignment CLN7 although the gene defect is still
unidentified. Another Turkish variant is caused by a defect in
the CLN8 gene, which is allelic to a mutation causing Northern
epilepsy [12]. A third variant is a specific “Turkish” mutation in
the CLN2 gene [5].
2.3.5. CLN1 and CTSD
An NCL disorder with late infantile onset can also be caused
by an unusual mutation in the CLN1 gene, as the age of onset of
symptoms resulting from defects in this gene was shown to have
a broad range [13]. The recent discovery of CTSD mutations in
a child presenting with ataxia and visual disturbance in early
school age and having progressive cognitive impairment, loss of
communication and ambulation suggests CTSD should be
considered a possible cause of variant late infantile or early
juvenile onset NCL [14].
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Juvenile NCL (JNCL) is usually caused by mutations in
CLN3. The leading sign of the juvenile type of neuronal ceroid
lipofuscinosis (JNCL, CLN3, juvenile onset Batten's disease,
Spielmeyer–Vogt syndrome) is almost invariably visual failure,
noticed around the age of 4 to 7 years, and leading to blindness
usually within a few years [15].
During the early school years, gradual psychomotor dete-
rioration becomes evident. When studying patients with the
intelligence quotient (IQ) measurement of the verbal Wechsler
Intelligence Scale for Children (WISC-R), a specific WISC-R
profile was found [16]. Comprehension and digit memory span
were already impaired at an early stage, whereas recognition of
similarities remained the best ability during follow-up.
The first epileptic seizure is noticed at the mean age of 10
years [17]. The predominant types of seizures are generalized
tonic–clonic seizures, but also partial seizures and myocolonic
jerks are noticed. With age, the seizures tend to increase in
frequency and severity. However, there is great individual
variability in the seizure control. In the electroencephalogram
(EEG), progressive background abnormality and an increase in
paroxysmal activity are seen [18].
Extrapyramidal symptoms, leading to impaired ability to
move around, are noticed in about half of the patients between
the ages of 12 and 15 years, and in the rest later [19]. In patients
with JNCL, the extrapyramidal signs include impaired balance,
rigidity, hypokinesia, stooped posture and shuffling gate,
whereas tremor, if seen, is usually mild and inconstant.
Dysarthria may also be regarded as one of the extrapyramidal
symptoms.
Patients with JNCL also suffer from a number of different
psychiatric symptoms. The most commonly reported symptoms
are social, thought, and attention problems, somatic complaints
and aggressive behaviour [20]. In addition, depression has been
reported. Sleep problems, including settling problems, noctur-
nal awakenings and nightmares may occur [21].
There is great inter- and intrafamilial variation in the clinical
course of the disease. In patients with the homozygous form of
the major mutation, the disease leads to premature death at a
mean age of 24 years, preceded by a 0–12 months bedridden
period [19].
A small number of children have been reported from
Scotland and elsewhere with presenting features very similar to
those of classical JNCL but who were found to be PPT1
deficient and have mutations in CLN1. Visual failure is the
leading symptom followed by psychomotor regression and
seizures. The long term outcome of these cases has not been
reported [22,23]. Recently mutations in CLN5 have also been
shown to be associated with a juvenile onset NCL phenotype in
children from Colombia [24]
3. Ophthalmological diagnosis of the NCLs
Visual failure is usually the leading symptom in juvenile
NCL. Other causes of isolated rapidly progressive visual failure
in young school aged children are rare but must be considered.The early retinal signs are subtle but experienced paediatric
neuro-ophthalmologists are able to recognise certain features.
The electrodiagnostic results are characteristic with a dimin-
ished or reduced retinogram and normal evoked potentials [25].
In the infantile and late infantile cases, visual failure is
accompanied by other more dominant symptoms, but the fundal
appearance and electrodiagnostics may be highly suggestive of
the diagnosis and prompt biochemical and genetic testing [26].
Late infantile NCL children show a very high amplitude visual
evoked response.
4. Neuro-radiological features
4.1. Infantile NCL (CLN1)
Thalami show a markedly decreased signal intensity to the
basal ganglia on T2-weighted MR images and increased signal
intensity on T1-weighted images from the start or even before
the clinical disease between the ages 7 and 11 months. In
addition, the signal intensity of the periventricular white matter
increases on T2-weighted images. Generalized cerebral and
cerebellar atrophy of varying degree is found by the age of 13
months [27,28].
4.2. Late infantile NCL (CLN2)
Severe cerebellar atrophy is a leading sign seen at the time of
the diagnosis on MRI [29]. Decreased signal intensity of the
thalami, in addition to increased signal intensity of the
periventricular white matter has been found in two patients at
the age of 4 years on T2-weighted images [30].
4.3. Finnish variant late infantile NCL (CLN5)
MRI shows cerebellar atrophy between the ages 4 and 7
years. Decreased signal intensity of the thalami and increased
signal intensity of the periventricular white matter and posterior
limbs of the internal capsules are seen on T2-weighted images at
the time of diagnosis [7,31].
4.4. Juvenile NCL (CLN3)
MRI is usually normal under the age of 10 years, thus not
useful for diagnosis. After the age of 14 years variable cerebral
and cerebellar atrophy appears. In addition, the thalami may
show abnormally low signal intensity and the periventricular
white matter high signal intensity on T2-weighted images from
the age of 11 years [32,33].
5. Biochemical diagnosis of the NCLs
Assay of white blood cell PPT1 and TPP1 activities are now
the mainstay of diagnosis for CLN1 and CLN2 related diseases.
The majority of these cases will present in the infantile and late
infantile age range with the typical clinical features as described
above. Some atypical cases will also be caused by mutations in
these genes and enzyme assay is important in young people with
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(such as CLN3 mutations analysis), in order to clarify the
diagnosis and point the way to further focused genetic testing.
In some services TPP1 and PPT1 assays are included in the
routine screen for lysosomal storage disorders. In others a
specific laboratory request must be made. Enzyme levels can be
measured using fresh blood samples [34,35], dried blood spots
[36], saliva samples [37] and cultured fibroblasts from a skin
biopsy, and results are generally available within a few weeks.
A high level of suspicion should remain if clinical, electro-
physiological features are suggestive of one of the NCLs but
enzyme levels are normal. It is recommended that a skin biopsy
is taken for ultrastructural analysis and fibroblast culture so that
enzyme assay can be repeated together with DNA studies.
TPP1 and PPT1 assay have been used for prenatal diagnosis
[34,35] but levels are not useful for carrier detection.
6. Genetic diagnosis of the NCLs
Mutations in CLN1 are responsible for infantile onset
neuronal ceroid lipofuscinosis and a number of variant cases
with later onset. In some series around half those with PPT
deficiency and/or mutations in CLN1 had onset of symptoms
later in childhood or adulthood [13], emphasising the need for
thorough biochemical and genetic investigation of all cases. The
gene encodes the enzyme palmitoyl protein thioesterase 1
(PPT1). Over 40 mutations have now been described in PPT1/
CLN1 including missense, nonsense, small deletions or
insertions, and mutations affecting splice sites. Mutations
leading to decreased enzyme stability and inactivity cause
infantile-onset CLN1 [38]. The disease is enriched in Finland
with an estimated carrier frequency of 1:70 [39]. Over 90% of
Finnish CLN1-patients are homozygous for a severe missense
point mutation (R122W) leading to enzyme inactivity. Different
PPT1 mutations are found in other parts of the world in patients
with infantile onset NCL. Half of all the PPT1 deficient patients
in USA had onset of symptoms in the infantile age range [15].
Children with infantile-onset NCL and PPT1 inactivity have
quite similar clinical features. Milder CLN1 mutations tend to
result in less severe disease with later age of onset in late
infantile, juvenile or adult age ranges [23,40,41].
Mutations in CLN2 result in decreased lysosomal tripeptidyl
transferase (TPP1) activity and classical late infantile onset
NCL [42]. Common mutations have been described in
Caucasian populations but a large number of other mutations
have now been described [3].
Mutation analysis of CLN1 and CLN2 adds little to the
diagnosis or management of the child, if enzyme deficiency has
already been established. A genetic mutation diagnosis is
essential however before carrier testing of other family
members or prenatal diagnosis can be attempted. Prenatal
testing using a combination of enzyme assay and mutation
testing in families where the biochemical and genetic diagnosis
is established is now reliable (38).
The diagnosis of classical JNCL is suggested by the clinical
features together with presence of vacuolated lymphocytes in
the peripheral blood and confirmed by CLN3 mutation analysis.The majority (>80%) of children of white Caucasian origin will
be homozygotes for the common 1 kb deletion [43], almost all
of the others will be compound heterozygotes for the 1 kb
deletion and another disease causing mutation which may be
unique to the family and thus cannot be screened for. Screening
for the 1 kb deletion is now widely available as a diagnostic
service [44,45]. Testing for other mutations is less readily
performed but may provide some prognostic information and be
necessary for prenatal and carrier testing.
For the rare cases where clinical, electrophysiological and
ultrastructural features suggest one of the NCLs but TPP1 and
PPT1 activities are normal, vacuolated lymphocytes are
negative and common mutations cannot be found, more
extensive genetic screening may be performed if clinically
indicated. Prioritising the NCL genes to be investigated will
depend on the ethnic origin of the family, the age of onset and
the constellation of clinical features. CTSD, CLN5, CLN6 and
CLN8 may all be targets for mutation analysis and/or
sequencing studies. Undoubtedly there are still some NCL
genes remaining to be identified. A genetic diagnosis is not yet
possible for all NCL cases although remains the aim.
Many European and North American centres are now able to
screen for the most common CLN1, CLN2 and CLN3 mutations
[46]. Details of international laboratories able to perform more
extensive diagnostic linkage studies and mutation analysis of
these and the other NCL genes are available on www.ucl.ac.uk/
ncl. Diagnosis, and the provision of information about the NCLs
to families and carers of affected children, however should not
be delayed pending genetic information but proceed on the basis
of the ultra-structural findings in individual cases.
7. Pathological diagnosis of the NCLS
Neuropathology in NCL is marked by two major features:
neuronal degeneration and accumulation of intracellular
lipopigments. The former is most likely to be responsible for
clinical symptoms, progression, and premature death of the
patient, the latter is of significant diagnostic concern.
Neuronal degeneration may commence in the dendritic tree
and may proceed to final neuronal loss which predominates in
cortical regions of the cerebrum (Fig. 1) and the cerebellum.
Neuronal depletion correlates with age of onset and duration of
the disease. It is usually most pronounced in infantile NCL and
(though not necessarily to the same extent) in late-onset forms
of disease caused by mutations in CLN1 while in juvenile NCL
it may be moderate and in adult NCL it may be rather mild.
Little is known about subcortical neuronal degeneration, as
quantitative data of subcortical nerve cell depletion have not yet
been established, but lack or loss of neuronal melanin in the
substantia nigra may be obvious in juvenile NCL. Early studies
[47] have shown that, in the cerebral cortex, small neurons of
layer II and pyramidal neurons of layer V appear to be more
affected than nerve cell populations of other cortical layers,
suggesting a disharmonious onset and progression of neuronal
damage among different nerve cell populations. Likewise,
documentation of significant neuronal cell loss in the peripheral
nervous system is also wanting. The retina is affected by
Fig. 1. Rarification of cerebral cortex due to severe depletion of neurons and
reactive gliosis, late-infantile type, FAN stain for astrocytes.
Fig. 2. Neuronal perikarya, including proximal axonal segments, enlarged by
autofluorescent lipopigments, adult type.
Fig. 3. Increased amounts of lipopigments contain subunit c of mitochondrial
ATPsynthase protein within nerve cells, adult type, immunohistochemistry.
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severe gliosis. However, the degree of retinal degeneration does
not correlate with that of cerebro- or cerebello-cortical atrophy
and, thus, not with clinical onset or duration of the disease. It is
present in each of the childhood forms of NCL, but most
pronounced in juvenile NCL. It is however not usually present
in adult NCL, except in the rare adult onset condition caused by
mutations in CLN1 [41].
Activation of microglia and astroglia appears not only to be
an early event, possibly even occurring before neuronal
degeneration [48], but remains abundant even in almost
completely depleted cerebral cortex (Fig. 1). Less is known
about the cellular reaction to possible neuronal loss in the
peripheral nervous system.
Lipopigments largely accrue in the perikarya of nerve (Figs. 1
and 2) and glial cells although formation of lipopigments often
expands into the proximal segment vicinal to the nerve cell body,
the respective axon forming an axon spindle (Fig. 1) or
meganeurite [49]. It appears that lipopigments are in continuous
extension within the nerve cell body and the adjacent axon
hillock, while in distant axonal stretches or within dendrites
lipopigments may only rarely and singly occur. Within the nerve
cell body lipopigment granules often appear grouped, their
accumulation taking place in enlarged neurons (except Purkinje
cells), especially in pyramidal cells of cortical layer III [47] and
many subcortical neurons, resulting in considerable enlarge-
ment, sometimes even in ballooning or in the Schaffer–
Spielmeyer process of the nerve cell body. Certain tinctorial
properties allow diagnostic hints of these lipopigments which
give a brownish hue when unstained, stain bright red with PAS
and blue with Luxol-fast blue, are autofluorescent (Fig. 2) and
display enhanced acid phosphatase activity, the marker enzyme
for lysosomes. Although the complete chemical composition of
lipopigments is not known, several components may beidentified by immunohistochemistry, foremost the subunit c of
mitochondrial ATP synthase (SCMAS) (Fig. 3) which prevails
in CLN2, CLN3 and late-infantile variants, and, though to a
lesser extent, sphingolipid activator proteins (SAPs) [50]. SAPs
predominate in CLN1 where SCMAS is only weakly present
[51]. The spectrum of accruing proteins in human NCL
lipopigments has not completely been documented but, for
instance, the amyloid precursor protein and β-amyloid protein
residues may also compose human NCL lipopigments [52].
SCMAS and SAPs may be employed as diagnostic markers
when encountering the Schaffer–Spielmeyer process or neuro-
nal ballooning owing to the, most often lysosomal, storage. Of
special diagnostic morphological significance may be the
demonstration of absent CLN2-specific enzyme protein TPP-1
in tissue samples. To our knowledge, a similar phenomenon has
not yet been shown for CLN1, i.e. immunohistochemical
absence of PPT-1 enzyme protein in tissue samples.
Although these light microscopic features of lipopigments
may be looked for when diagnosing NCL in extracerebral
tissues, largely by biopsy rather than autopsy, such findings are
not as reliable or helpful in the classification of NCL type as are
the ultrastructural features of lipopigments. In addition there are
Fig. 4. Granular lipopigment in an endothelial cell, infantile type.
Fig. 6. Membrane-bound vacuoles within a blood lymphocyte, juvenile type.
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may be identified by electron microscopy, but escape light
microscopic recognition, and also the confounding presence of
regular lipofuscin or age pigment.
The ultrastructure of lipopigments in NCL is heterogeneous
when compared to regular lipofuscin or vitamin-E deficiency
lipopigment. The genotype–morphotype correlation is very
strong: CLN1, irrespective of clinical onset and, thus, clinical
subtype, demonstrates a granular pattern (Fig. 4); CLN2 a pure
curvilinear pattern (Fig. 5), CLN3 is marked by fingerprint
profiles, and CLN5, CLN6 and CLN7 entail fingerprint profiles.
This genotype–morphotype correlation is particularly evident
in blood lymphocytes in which the late-infantile variants CLN5,
CLN6, CLN7 are associated with avacuolar fingerprint-contain-
ing lipopigments while in CLN3 those fingerprint profiles are
within lysosomal vacuoles (Figs. 6 and 7). CTSD has also been
associated with granular storage material. However, lipopig-
ment formation in blood lymphocytes has not yet been
documented in adult NCL.
Since lipopigment formation is near-ubiquitous in extracer-
ebral tissues, skin, skeletal muscle (Fig. 4), conjunctiva, liver,Fig. 5. Curvilinear bodies in vascular smooth muscle cells, late-infantile type.and rectum (or other intestinal segments) may be useful
diagnostic morphological targets. Skin contains a multitude of
diverse subtypes of cells among which secretory cells of eccrine
sweat gland epithelia, non-vascular and vascular smooth muscle
cells (Fig. 6), as well as other mural cells of vessels (Fig. 5) and,
though more rarely, dermal nerve fascicles may display NCL-
typical lipopigments. In skeletal muscle fibres, only two types
of NCL-specific lipopigments may be encountered, granular
ones in CLN1 and curvilinear–rectilinear bodies in the
remaining childhood forms, though sometimes in adult NCL,
too. Muscle biopsy is therefore a less useful tool for the
classification of NCL types
Although prenatal diagnosis in most childhood forms of
NCL may now successfully be based on molecular genetic
studies and biochemical enzyme assays, prenatal biopsy may be
initiated for confirmation of molecular studies or when the latter
are not available. Then, chorionic biopsies may show granular
lipopigments in stromal vessel walls in CLN1, and some ill-
defined inclusions in CLN3. Curvilinear bodies may be seen in
amniotic fluid cells in CLN2 [53], while no prenatalFig. 7. Occasionally, a small lipopigment granule with fingerprint lamellae
(arrows) is present within a membrane-bound lysosomal vacuole of a blood
lymphocyte, juvenile type.
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variants CLN5 to CLN8.
8. Summary
The clinical features of this group of disorders are now very
well described and increasingly recognised. Advances in
research have enabled diagnosis at the molecular genetic and
biochemical levels, and resulted in prenatal diagnosis and
carrier testing availability for many families affected by the
NCLs. Diagnostic testing can now be directed and focused,
being directed largely by the clinical phenotype and ethnic
background of the child, together with ultrastructural studies of
abnormal storage material in neurons and other cells in atypical
and unusual cases. Enzyme analysis and mutation detection for
the most common mutations have become routine, and now
replace intrusive investigations such as rectal biopsy for the
majority of cases.
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